Metabolic Outcomes, Bone Health, and Risk of Polycystic Ovary Syndrome in Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogues.

Faienza MF, Brunetti G, Acquafredda A, Delvecchio M, Lonero A, Gaeta A, Suavo Bulzis P, Corica D, Velletri MR, De Luca F, Cavallo L, Wasniewska M

Hormone research in paediatrics7 Apr 2017Cited by 28 (Europe PMC)

PMID28391271DOI10.1159/000456546PepBankPUB-28391271

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, BMI was similar after triptorelin treatment and without treatment.
In plain wordsIn girls with early puberty, previous triptorelin treatment was linked to similar BMI compared with no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBody mass index
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
The 2 groups were similar for body mass index (BMI) and waist circumference.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127101
02HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, waist circumference was similar after triptorelin treatment and without treatment.
In plain wordsIn girls with early puberty, previous triptorelin treatment was linked to similar waist circumference compared with no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeWaist circumference
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
The 2 groups were similar for body mass index (BMI) and waist circumference.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127102
03HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, previous triptorelin treatment was associated with higher HOMA-IR than no treatment.
In plain wordsIn girls with early puberty, previous triptorelin treatment was linked to higher insulin resistance than no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHOMA-IR
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
HOMA-IR, dehydroepi-androsterone sulfate, and Δ4-androstenedione were higher in the treated than in the untreated subjects (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127103
04HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, dehydroepiandrosterone sulfate was higher after triptorelin treatment than without treatment.
In plain wordsIn girls with early puberty, previous triptorelin treatment was linked to higher dehydroepiandrosterone sulfate than no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseDehydroepiandrosterone sulfate
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
HOMA-IR, dehydroepi-androsterone sulfate, and Δ4-androstenedione were higher in the treated than in the untreated subjects (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127104
05HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, Δ4-androstenedione was higher after triptorelin treatment than without treatment.
In plain wordsIn girls with early puberty, previous triptorelin treatment was linked to higher androstenedione than no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseΔ4-androstenedione
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
HOMA-IR, dehydroepi-androsterone sulfate, and Δ4-androstenedione were higher in the treated than in the untreated subjects (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127105
06HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, amplitude-dependent speed of sound differed significantly between previously triptorelin-treated and untreated groups.
In plain wordsIn girls with early puberty, a bone ultrasound measure differed between previously triptorelin-treated and untreated groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedAmplitude-dependent speed of sound
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
Significant differences were found for amplitude-dependent speed of sound (p < 0.03) and bone transmission time z-scores (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127106
07HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, bone transmission time z-scores differed significantly between previously triptorelin-treated and untreated groups.
In plain wordsIn girls with early puberty, bone transmission time scores differed between previously triptorelin-treated and untreated groups.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedBone transmission time z-score
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
Significant differences were found for amplitude-dependent speed of sound (p < 0.03) and bone transmission time z-scores (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127107
08HumanObservational studyEfficacy outcome
In girls with idiopathic central precocious puberty, PCOS prevalence was higher after triptorelin treatment than without treatment.
In plain wordsIn girls with early puberty, previous triptorelin treatment was linked to more polycystic ovary syndrome than no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePolycystic ovary syndrome prevalence
Study
n = 94
Comparator
Untreated girls with idiopathic central precocious puberty
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 3.4 ± 0.6 yearsAs given in this study (human).
Source sentences
Summary
The prevalence of PCOS was higher in the treated than in the untreated subjects (p < 0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 94 ICPP girls who were at least 2 years after menarche and had already attained adult height at the time of the study: 56 previously treated with depot triptorelin (3.4 ± 0.6 years) and 38 untreated.
Report a problemFND-2839127108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.